In vivo repaglinide prominently prolonged the median survival time of mice bearing orthotopic glioma, reducing Bcl-2, Beclin-1 and PD-L1 expression in glioma tissues and indicating that repaglinide may exert its anti-cancer effects via apoptotic, autophagic and immune checkpoint signaling [84]. This evidence concerns the gene BECN1 and central nervous system cancer.